CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors F
Post# of 325
(Total Views: 190)
Posted On: 12/14/2022 4:31:02 PM
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment
- John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter
- The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023
- CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials in mid-2023
- Through its research, CNS looks to tap into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019
On September 30, 2022, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, Glioblastoma Multiforme (“GBM”), and neuro-oncology, released its financial results for the third quarter of the 2022 financial year (“Q3 2022”). While making the announcement, John Climaco, CNS’s CEO, lauded the company’s progress, highlighting the successful expansion of its pivotal Berubicin trial into Europe within the quarter. He further noted how the move was integral to the company achieving interim analysis by mid-2023 which, he believes, will be a transformational milestone (https://nnw.fm/IVrZp ).
CNS has, since its inception, shown its commitment to solving the unmet need associated with the treatment of GBM. This condition affects approximately 13,000 people in the United States each year. It is estimated that up to 50% of original malignant tumors of the central nervous system (“CNS”) are glioblastomas, with diagnosed patients having an average time of about a year after diagnosis and only 10% or less surviving to five years (https://nnw.fm/Je5bR ).
Despite this prevalence, treatment options for GBM are scarce, and CNS hopes to address this with its lead drug candidate, Berubicin. Regarded as an innovative first-in-its-class anthracycline to appear to cross over the blood-brain barrier and kill tumor cells as a potential treatment option for GBM, Berubicin has shown great promise in the clinical trials conducted thus far. For example, at least 44% of patients in a recent clinical trial showed a clinical response, with one demonstrating a lack of detectable cancer cells following the study (https://nnw.fm/aufMH ).
As it works toward interim analysis of clinical trials in mid-2023, CNS looks to build on the successful patient enrollment and dosing in France, which, so far, brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe. The company also looks to build momentum to advance its program across the finish line.
“This expansion into Europe drives us toward our goal of interim analysis, expected in mid-2023, which we believe has the potential to be (a) transformational milestone. Moving forward, we are focused on building momentum and advancing this important program across the finish line,” noted Mr. Climaco (https://nnw.fm/fr3GQ ).
Mr. Climaco emphasizes that CNS’s focus and priorities are firmly anchored in advancing its clinical development for Berubicin to bring meaningful treatment to GBM patients. He further notes that this focus is driven by a significant unmet need, particularly given that recurrent GBM does not have an “approved therapy anywhere in the world.”
Through this research, CNS inches closer to tapping into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019. In addition, it looks to offer a potentially viable solution to GBM, a condition that currently affects as many as 5 out of every 100,000 individuals (https://nnw.fm/5BtZg ).
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter
- The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023
- CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials in mid-2023
- Through its research, CNS looks to tap into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019
On September 30, 2022, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, Glioblastoma Multiforme (“GBM”), and neuro-oncology, released its financial results for the third quarter of the 2022 financial year (“Q3 2022”). While making the announcement, John Climaco, CNS’s CEO, lauded the company’s progress, highlighting the successful expansion of its pivotal Berubicin trial into Europe within the quarter. He further noted how the move was integral to the company achieving interim analysis by mid-2023 which, he believes, will be a transformational milestone (https://nnw.fm/IVrZp ).
CNS has, since its inception, shown its commitment to solving the unmet need associated with the treatment of GBM. This condition affects approximately 13,000 people in the United States each year. It is estimated that up to 50% of original malignant tumors of the central nervous system (“CNS”) are glioblastomas, with diagnosed patients having an average time of about a year after diagnosis and only 10% or less surviving to five years (https://nnw.fm/Je5bR ).
Despite this prevalence, treatment options for GBM are scarce, and CNS hopes to address this with its lead drug candidate, Berubicin. Regarded as an innovative first-in-its-class anthracycline to appear to cross over the blood-brain barrier and kill tumor cells as a potential treatment option for GBM, Berubicin has shown great promise in the clinical trials conducted thus far. For example, at least 44% of patients in a recent clinical trial showed a clinical response, with one demonstrating a lack of detectable cancer cells following the study (https://nnw.fm/aufMH ).
As it works toward interim analysis of clinical trials in mid-2023, CNS looks to build on the successful patient enrollment and dosing in France, which, so far, brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe. The company also looks to build momentum to advance its program across the finish line.
“This expansion into Europe drives us toward our goal of interim analysis, expected in mid-2023, which we believe has the potential to be (a) transformational milestone. Moving forward, we are focused on building momentum and advancing this important program across the finish line,” noted Mr. Climaco (https://nnw.fm/fr3GQ ).
Mr. Climaco emphasizes that CNS’s focus and priorities are firmly anchored in advancing its clinical development for Berubicin to bring meaningful treatment to GBM patients. He further notes that this focus is driven by a significant unmet need, particularly given that recurrent GBM does not have an “approved therapy anywhere in the world.”
Through this research, CNS inches closer to tapping into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019. In addition, it looks to offer a potentially viable solution to GBM, a condition that currently affects as many as 5 out of every 100,000 individuals (https://nnw.fm/5BtZg ).
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CNS Pharmaceuticals Inc. (CNSP) Stock Research Links
Scroll down for more posts ▼